pharma news today glp-1 obesity drugs Upcoming wave of hormone-based therapies set to change field of diabetes, care GLP-1 Drug Market: the rapid
Description
This helps identify competitive pressure points, partnership opportunities, and routes to differentiation
Authorised and Regulated by:
Of these, GLP-1 RAs are generally preferred because of their demonstrated cardiovascular benefits and potential for improved renal outcomes [2]
Novo Nordisk also agreed to spend up to $1.1 billion last year to acquire Inversago Pharma, gaining an experimental oral drug called monlunabant thats designed to block a cannabinoid receptor important in regulating appetite
'Maritide is a true differentiation compared to what's available in the market', said Amgen's Murdo Gordon
